Organic nitrates: Past, Present and Future

Molecules

Volumn 19, Issue 9, 2014, Pages 15314-15323

  França Silva, Maria S ^a   Balarini, Camille M ^a   Cruz, Josiane C ^a   Khan, Barkat A ^b   Rampelotto, Pabulo H ^c   Braga, Valdir A ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

^b THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^c UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

1,3 dibutoxy 2 propyl nitrate; Nitrate tolerance; Organics nitrates

Indexed keywords

NITRIC ACID DERIVATIVE; NITRIC OXIDE DONOR; ORGANIC COMPOUND;

CHEMISTRY; HUMAN;

HUMANS; NITRATES; NITRIC OXIDE DONORS; ORGANIC CHEMICALS;

EID: 84907907897     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules190915314     Document Type: Review

References (38)

1. Moncada, S.; Higgs, A. Mechanisms of disease: The L-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329, 2002-2012.
2. Rudolph, V.; Freeman, B.A. Cardiovascular consequences when nitric oxide and lipid signaling converge. Circ. Res. 2009, 105, 511-522.
3. Pörsti, I.; Paakkari, I. Nitric oxide-based possibilities for pharmacotherapy. Ann. Med. 1995, 27, 407-420.
4. Wang, P.G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. Nitric oxide donors: Chemical activities and biological applications. Chem. Rev. 2002, 102, 1091-1134.
5. Miller, M.R.; Wadsworth, R.M. Understanding organic nitrates-A vein hope? Br. J. Pharmacol. 2009, 157, 565-567.
6. Münzel, T.; Daiber, A.; Mülsch, A. Explaining the phenomenon of nitrate tolerance. Circ. Res. 2005, 97, 618-628.
7. Follmann, M.; Griebenow, N.; Hahn, M.G.; Hartung, I.; Mais, F.J.; Mittendorf, J.; Schäfer, M.; Schirok, H.; Stasch, JP.; Stoll, F.; et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew. Chem. Int. Ed. Engl. 2013, 52, 9442-9462.
8. Murrel, W. Nitroglycerine as a remedy for angina pectoris. Lancet 1879, 1, 80-81.
9. Marsh, N.; Marsh, A. A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin. Exp. Pharmacol. Physiol. 2000, 27, 313-319.
10. Arnold, W.P.; Mittal, C.K.; Katsuki, S.; Murad, F. Nitric oxide activates guanylate cyclase and increases guanosine 3':5'-cyclic monophosphate levels in various tissue preparations. Proc. Natl. Acad. Sci. USA 1977, 74, 3203-3207.
11. Furchgott, R.F. Endothelium-derived relaxing factor: discovery, early studies, and identification as nitric oxide. Biosci. Rep. 1999, 19, 235-251.
12. Bode-Böger, S.M.; Kojda, G. Organic nitrates in cardiovascular disease. Cell. Mol. Biol. 2005, 51, 307-320.
13. Münzel, T.; Daiber, A.; Gori, T. Nitrate therapy: New aspects concerning molecular action and tolerance. Circulation 2011, 123, 2132-2144.
14. Mayer, B.; Beretta, M. The enigma of nitroglycerin bioactivation and nitrate tolerance: News, views and troubles. Br. J. Pharmacol. 2008, 155, 170-184.
15. Münzel, T.; Gori, T. Nitrate therapy and nitrate tolerance in patients with coronary artery disease. Curr. Opin. Pharmacol. 2013, 13, 251-259.
16. Furchgott, R.F. Role of endothelium in responses of vascular smooth muscle. Circ. Res. 1983, 53, 557-573.
17. Hilgers, R.H.; Webb, R.C. Molecular aspects of arterial smooth muscle contraction: Focuson Rho. Exp. Biol. Med. 2005, 230, 829-835.
18. Irvine, J.C.; Favaloro, J.L.; Kemp-Harper, B.K. NO-activates soluble guanylate cyclase and Kv channels to vasodilate resistance arteries. Hypertension 2003, 41, 1301-1307.
19. Vanhoutte, P.M.; Boulanger, C.M. Function of the endothelium in arterial hypertension. Rev. Prat. 1995, 45, 2513-2518.
20. Bolotina, V.M.; Najibi, S.; Palacino, J.J.; Pagano, P.J.; Cohen, R.A. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994, 368, 850-853.
21. Fox, K.; Garcia, M.A.; Ardissino, D.; Buszman, P.; Camici, P.G.; Crea, F.; Daly, C.; de Backer, G.; Hjemdahl, P.; Lopez-Sendon, J.; et al. Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary. Eur. Heart J. 2006, 27, 1341-1381.
22. Gayet, J.L.; Paganelli, F.; Cohen-Solal, A. Update on the medical treatment of stable angina. Arch. Cardiovasc. Dis. 2011, 104, 536-544.
23. Thadani, U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc. Drugs Ther. 1997, 10, 735-742.
24. Kalidindi, M.; Velauthar, L.; Khan, K.; Aquilina, J. The role of nitrates in the prevention of preeclampsia: An update. Curr. Opin. Obstet. Gynecol. 2012, 24, 361-367.
25. Johal, T.; Lees, C.C.; Everett, T.R.; Wilkinson, I.B. The nitricoxide pathway and possible therapeutic options in pre-eclampsia. Br. J. Clin. Pharmacol. 2013, doi:10.1111/bcp.12301.
26. Maul, H.; Longo, M.; Saade, G.R.; Garfield, R.E. Nitricoxide and its role during pregnancy: From ovulation to delivery. Curr. Pharm. Des. 2003, 9, 359-380.
27. Meher, S.; Duley, L. Nitricoxide for preventing pre-eclampsia and its complications. Cochrane Database Syst. Rev. 2007, 18, doi:10.1002/14651858.CD006490.
28. Galiè, N.; Hoeper, M.M.; Humbert, M.; Torbicki, A.; Vachiery, J.L.; Barbera, J.A.; Beghetti, M.; Corris, P.; Gaine, S.; Gibbs, J.S.; et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2009, 34, 1219-1263.
29. O?Callaghan, D.S.; Savale, L.; Montani, D.; Jaïs, X.; Sitbon, O.; Simonneau, G.; Humbert, M. Treatment of pulmonary arterial hypertension with targeted therapies. Nat. Rev. Cardiol. 2011, 8, 526-538.
30. Mentzer, S.J.; Reilly, J.J.; DeCamp, M.; Sugarbaker, D.J.; Faller, D.V. Potential mechanism of vasomotor dysregulation after lung transplantation for primary pulmonary hypertension. J. Heart Lung Transplant. 1995, 14, 387-393.
31. Brandler, M.D.; Powell, S.C.; Craig, D.M.; Quick, G.; McMahon, T.J.; Goldberg, R.N.; Stamler, J.S. A novel inhaled organic nitrate that affects pulmonary vascular tone in a piglet model of hypoxia-induced pulmonary hypertension. Pediatr. Res. 2005, 58, 531-536.
32. Klemenska, E.; Ber?sewicz, A. Bioactivation of organic nitrates and the mechanism of nitrate tolerance. Cardiol. J. 2009, 16, 11-19.
33. Dikalov, S.; Fink, B.; Skatchkov, M.; Stalleicken, D.; Bassenge, E. Formation of Reactive Oxygen Species by Pentaerithrityltetranitrate and Glyceryl Trinitrate in Vitro and Development of Nitrate Tolerance. J. Pharmacol. Exp. Ther. 1998, 286, 938-944.
34. França-Silva, M.S.; Luciano, M.N.; Ribeiro, T.P.; Silva, J.S.F.; Santos, A.F.; França, K.C.; Nakao, L.S.; Athayde-Filho, P.F.; Braga, V.A.; Medeiros, I.A. The 2-nitrate-1,3-dibuthoxypropan, a new nitric oxide donor, induces vasorelaxation in mesenteric arteries of the rat. Eur. J. Pharmacol. 2012, 690, 170-175.
35. França-Silva, M.S.; Balarini, C.M.; Cruz, J.C.; Khan, B.A.; Santos, A.F.; Athayde-Filho, P.F.; Braga, V.A. Developing new organic nitrates for treating hypertension: A review. Exp. Clin. Cardiol. 2014, in press.
36. França-Silva, M.S.; Monteiro, M.M.O.; Queiroz, T.M.; Santos, A.F.; Athayde-Filho, P.F.; Braga, V.A. The new nitric oxide donor 2-nitrate-1,3-dibuthoxypropan alters autonomic function in spontaneously hypertensive rats. Auton. Neurosci. 2012, 171, 28-35.
37. Queiroz, T.M.; Mendes-Júnior, L.G.; Guimarães, D.D.; França-Silva, M.S.; Nalivaiko, E.; Braga, V.A. Cardiorespiratory effects induced by 2-nitrate-1,3-dibuthoxypropan are reduced by nitric oxide scavenger in rats. Auton. Neurosci. 2014, 181, 31-36.
38. Daiber, A.; Oelze, M.; Coldewey, M.; Bachschmid, M.; Wenzel, P.; Sydow, K.; Wendt, M.; Kleschyov, A.L.; Stalleicken, D.; Ullrich, V.; et al. Oxidative stress and mitochondrial aldehyde dehydrogenase activity: A comparison of pentaerythritol tetranitrate with other organic nitrates. Mol. Pharmacol. 2004, 66, 1372-1382.